Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445148 | 0.86 | KDM4E (0.58) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL30343148 | 0.86 | KDM4E (0.58) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL2722518 | 0.81 | BRD4 (0.60) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL18307135 | 0.79 | BRD4 (0.50) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL19030688 | 0.79 | BRD4 (0.61) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL17027265 | 0.79 | BRD4 (0.56) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL29706799 | 0.79 | BRD4 (0.61) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL1396628 | 0.79 | BRD4 (0.56) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL13574297 | 0.79 | BRD4 (0.50) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B | |
| SCHEMBL3588753 | 0.79 | BRD4 (0.50) | BRD4KDM4EALDH1A1SMN1; SMN2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-2883870-B1 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-10-24 | — | — | EP | disclosed |
| EP-3112354-B1 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-07-25 | — | — | EP | disclosed |
| EP-3112354-B1 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-9751846-B2 | Method for producing 1,4-benzoxazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751846-B2 | Method for producing 1,4-benzoxazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-09-05 | — | — | US | disclosed |
| EP-3112354-A1 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-01-04 | — | — | EP | disclosed |
| EP-3112354-A1 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160362385-A1 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
| US-20160362385-A1 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-15 | — | — | US | disclosed |
| EP-1984345-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312233-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | EVOTEC AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205773-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | BRD4 2304/4885KDM4E 4112/4885ALDH1A1 1821/4885 |
| US-20060194801-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | BRD4 2304/4885KDM4E 4112/4885ALDH1A1 1821/4885 |
| US-20160362385-A1 | METHOD FOR PRODUCING 1,4-BENZOXAZINE COMPOUND | BRSK1, BRSK2, MSMO1 | BRD4 29/4885KDM4E 476/4885ALDH1A1 840/4885 |
| US-20080096919-A1 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | TRPV1, TRPA1, TRPV2 | BRD4 2304/4885KDM4E 4112/4885ALDH1A1 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.